mRNA Cancer Vaccines Trigger Tumor Responses Through an Unexpected Immune Pathway
Scientists at Washington University School of Medicine in St. Louis have found that mRNA cancer vaccines can generate strong anti-tumor immune responses even when the immune cell long believed essential to the process is entirely absent. The findings, published in Nature on July 9, 2026, challenge a foundational assumption in cancer immunology and point toward a built-in backup that researchers did not know existed.
The discovery that surprised researchers
For years, scientists assumed that a dendritic cell subtype called cDC1 was the necessary driver of T-cell responses to mRNA vaccines. cDC1 cells are considered among the immune system's most effective instructors, activating T cells to hunt and destroy cells the vaccine flags as threats. The assumption held across decades of research on viral vaccines and appeared likely to carry over to cancer vaccines.
It did not. When researchers used mouse models that lacked cDC1 cells entirely, the mRNA vaccines still produced strong T-cell responses. In one set of experiments, mice without cDC1 cleared sarcoma tumors after vaccination. Something else was doing the work.
That turned out to be cDC2, a related but distinct dendritic cell subtype. Under normal circumstances, cDC2 cells are not known to contribute meaningfully to vaccine responses. Without cDC1, they stepped in and drove the anti-tumor response. "By dissecting which immune cells are involved and how they coordinate the response," said senior author Kenneth Murphy, "we are offering vaccine developers some additional mechanistic insights to consider in their goal of optimizing these vaccines against tumor proteins."
Why this matters for cancer treatment
The COVID-19 pandemic put mRNA vaccine technology into broad public view, but cancer researchers have been working with it for longer. mRNA cancer vaccines are currently in clinical trials for melanoma, small cell lung cancer, bladder cancer, and pancreatic cancer. Each vaccine is designed to train the immune system to recognize specific tumor proteins — molecular fingerprints unique to an individual patient's cancer — and destroy cells bearing them.
Understanding that cDC2 can substitute for cDC1 is practically useful. Some tumors actively suppress immune cell activity. Some patients have conditions that affect dendritic cell populations. A vaccine designed around cDC1 alone could fail in the patients who need it most. Knowing a backup pathway exists changes how researchers might approach design and testing.
The finding also helps account for some past results that were harder to explain. Mice and patients who responded well to mRNA vaccines despite compromised cDC1 function may have been benefiting from this secondary mechanism without anyone realizing it.
Where mRNA cancer vaccines stand today
The clinical picture for mRNA cancer vaccines has improved substantially over the past three years. At Memorial Sloan Kettering, follow-up data from a phase 1 trial using BioNTech's personalized mRNA vaccine for pancreatic cancer showed that nearly 90% of patients whose immune systems responded to the vaccine were still alive up to six years after treatment. The five-year survival rate for pancreatic cancer without treatment is approximately 13%.
Moderna and Merck are running a large-scale trial of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda for melanoma. In January 2026, they reported the combination cut the death rate by 49% over five years in their study group. A phase 3 trial is now underway, and the companies are testing the same approach against non-small cell lung cancer, bladder cancer, and renal cell carcinoma.
The WashU study does not alter any ongoing trials. What it does is expand the map of how mRNA vaccination works at a cellular level. That kind of basic science tends to feed the next generation of treatments. Vaccine designers who now know cDC2 can carry the response when cDC1 is missing will factor that into whatever they build next — including vaccines for patients whose immune systems do not fit the standard model.